EUVIMEDPoznaj EUVIMED
Übersichtsarbeit

Growth and endocrine function in thalassemia major in childhood and adolescence

M Delvecchio, L Cavallo

Journal of Endocrinological Investigation · 2010-01 · 33 (1) · 61-68

DOI: 10.1007/bf03346551 ↗

At a glance

Übersichtsarbeit in Journal of Endocrinological Investigation, published online on 2014-03-27. Written by M Delvecchio and 1 co-authors. Institution: Unità Operativa Complessa di Pediatria, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. Cited 48 times so far (Crossref); 123 references.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

BACKGROUND: Thalassemia major is an inherited hemoglobin disorder characterized by chronic anemia and iron overload due to transfusion therapy and gastrointestinal absorption. Iron overload causes most of the associated mortality and morbidity and frequently involves the endocrine glands. AIM: To review the most pertinent literature on the topic. METHODS: One hundred and twenty-three papers were evaluated. RESULTS: Disproportionate short stature is frequent and becomes more evident at puberty because of the lack of growth spurt. Later on, partial height recovery may occur. Long-term treatment with recombinant human GH seems ineffective to improve final height. Pubertal development is characterized by a clinical spectrum ranging from hypogonadism to a simple delay in starting and developing of puberty. Hormonal replacement is mandatory in cases of absent or arrested puberty. Pancreatic beta-cells function may be impaired during adolescence or later on. Its impairment ranges from hyperinsulinemia, secondary to insulin resistance, with normal glucose tolerance to beta-cells failure with insulin-dependent diabetes mellitus. Primary hypothyroidism may affect thalassemic patients from the second decade of life. The thyroid dysfunction may be reversible (if an intensive chelation therapy regimen is started in the precocious phase), stationary, or slowly progressive. Central hypothyroidism is less common and autoimmune thyroiditis absent. CONCLUSION: Despite the improvement of the treatment, the involvement of the endocrine system still burdens the life of these patients. Further therapeutic improvement would reasonably reduce morbidity and, hopefully, mortality of thalassemic patients and make the endocrine disorders easier to treat.

Subjects

MeSH terms (MEDLINE)

AdolescentChildChild DevelopmentChild, PreschoolDiabetes Mellitus, Type 1Growth DisordersHuman Growth HormoneHumansHypothyroidismIron OverloadPuberty, DelayedRecombinant ProteinsThyroid Glandbeta-Thalassemia

Substances

Recombinant ProteinsHuman Growth Hormone

Authors and institutions

  • Unità Operativa Complessa di Pediatria, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.

Cite

APA

Delvecchio, M., & Cavallo, L. (2010). Growth and endocrine function in thalassemia major in childhood and adolescence. Journal of Endocrinological Investigation, 33(1), 61-68. https://doi.org/10.1007/bf03346551

Vancouver

Delvecchio M, Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. Journal of Endocrinological Investigation. 2010;33(1):61-68. doi:10.1007/bf03346551

BibTeX
@article{Delvecchio2010,
  author = {Delvecchio, M and Cavallo, L},
  title = {Growth and endocrine function in thalassemia major in childhood and adolescence},
  journal = {Journal of Endocrinological Investigation},
  year = {2010},
  volume = {33},
  number = {1},
  pages = {61--68},
  doi = {10.1007/bf03346551}
}
Start for free →